Amplifon analyst consensus in focus, shares on Borsa Italiana radar

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 12:40.

Amplifon (IT0004056880) enters the new week with investors watching its analyst consensus and growth trajectory. The Milan-listed hearing-care group is a mid-cap name on Borsa Italiana, with the stock widely covered by European brokerages that track its store expansion and margin profile.

What analysts track today

Amplifon operates as a global leader in hearing-aid retail and services, and brokers tend to frame the stock through like-for-like sales, store openings and earnings-per-share growth. Consensus models usually follow revenue, EBITDA margin and net income trends over a rolling three-year horizon, reflecting the company’s long-term expansion plans.

Coverage from major houses such as UBS, Deutsche Bank and other European brokers typically centers on Amplifon’s positioning versus global peers in hearing-care retail, focusing on market share in key regions like Europe and North America. Analyst notes often compare Amplifon’s growth and profitability to diversified medical-technology names or consumer-health players that compete for capital allocation.

Consensus estimates and rating mix

On a typical consensus snapshot, most firms assign Amplifon either Buy or Hold ratings, with price targets based on discounted cash-flow models or multiples of earnings and EBITDA. The rating mix gives investors a structured view of how the stock’s valuation sits versus expected earnings, while target prices set medium-term reference points for performance assessment.

Consensus projections generally assume continued revenue growth driven by store network expansion, cross-selling of services and incremental penetration of aging populations needing hearing solutions. Analysts also incorporate assumptions for operating leverage, where higher sales per store and efficiency in back-office functions can lift profitability over time.

The business behind the numbers

Amplifon generates its revenue primarily by selling hearing aids and related services through a global retail footprint. Typical stores offer hearing tests, fitting services and aftercare, aiming to build recurring customer relationships that support stable cash flows and visibility on future revenue.

The company’s business model combines product sales with service income, which can provide a blend of hardware margins and recurring fees. This mix helps analysts model long-term cash generation, since follow-up consultations, device upgrades and maintenance contribute to ongoing earnings beyond the initial sale.

Where the stock trades today

Amplifon shares (IT0004056880) trade on Borsa Italiana in Milan, with prices quoted in euros throughout the trading day. As of 2026-06-30, 12:40, the shares are listed on the Italian exchange, and investors follow intraday moves and liquidity via local market data and broker platforms.

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. All data and assessments are based on publicly available information believed to be reliable at the time of writing, but they may change without notice. Investors should conduct their own research and consult a qualified advisor before making investment decisions.